Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
Bristol-Myers Squibb Co (NYSE: BMY) shares spiked 4.5 percent Tuesday on news that Carl Icahn bought a stake in the company. According to the Wall Street Journal, Icahn allegedly considers Bristol-Myers a potential takeover target.
Earlier Tuesday, Bristol-Myers reported a $2 billion accelerated buyback.
The investor's expectation corroborates a January Bloomberg report acknowledging Bristol-Myers' fall from the fourth-best to the ninth-best biopharmaceutical company in the US. The company’s struggle to push its lung cancer drug, Opdivo, set it well behind competitor Merck & Co., Inc. (NYSE: MRK) and prompted a two-year plunge in stock value.
Now, as a more affordable company with a promising blood thinner and a potential use for Opdivo in melanoma and kidney cancer treatments, Bristol-Myers is well positioned for a buyout.
Related Link: Here's What Merck's Keytruda News Means For Bristol-Myers
Jefferies analyst Jeffrey Holford suggested in a recent note the company may appeal to Sanofi SA (ADR) (NYSE: SNY), Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE) and Novartis AG (ADR) (NYSE: NVS) — but not likely Amgen, Inc. (NASDAQ: AMGN) or Gilead Science, Inc. (NASDAQ: GILD).
Meanwhile, Deutsche Bank analysts proposed Pfizer would likely be deterred by the short-term risk of immuno-oncology trials and wouldn't make a bid.
Bristol-Myers stock waned from its post-news peak and traded at $54.78 at the time of publication.
See more from Benzinga
Advanced Micro Devices Establishes New 2017 High As New Ryzen Processors To Ship Next Week
When Will Taser's Impressive Revenue Growth Translate To The Bottom Line?
T-Mobile Continues To Gobble Up Market Share, Now 3rd Place In The U.S.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.